相关实验视频
Updated: Jun 29, 2025
07:45
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
Published on: March 4, 2021
3.3K
6-thioguanine的眼部药理和生物化学概况:一种药物重定向研究
Maria Consiglia Trotta1, Carlo Gesualdo2, Caterina Claudia Lepre1
1Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Frontiers in pharmacology
|April 9, 2024
概括
精氨酸类比的6-thioguanine (6TG) 通过与MC1R和MC5R受体相互作用,在糖尿病视网膜病变 (DR) 中表现出抗血管原作用. 这种药物可能通过抑制异常的血管生长来为DR治疗提供新的治疗途径.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 糖尿病视网膜病变 (DR) 是导致视力丧失的主要原因,其特征是异常的血管生长 (血管生成).
- 精氨酸类比的6-thioguanine (6TG) 是一种用于急性髓性白血病 (AML) 的已知药物,其在治疗DR的潜力之前尚未被探索.
研究的目的:
- 在糖尿病视网膜病变 (DR) 的背景下研究6TG的抗血管性潜力.
- 探索6TG作用背后的分子机制,特别是其与黑色素皮质受体 (MC1R和MC5R) 的相互作用.
主要方法:
- 计算分子建模以评估6TG与MC1R和MC5R的结合亲和力.
- 使用暴露在高葡萄糖中的人类静脉内皮细胞 (HUVEC) 进行体外研究,以评估细胞活力和管形成.
- 在活体研究中,小鼠模型的链毒素诱导的糖尿病,以评估内6TG对视网膜新血管化的影响,使用光素血管学和CD34染色.
主要成果:
- 计算分析显示,6TG与MC5R的结合比MC1R更稳定.
- 在糖尿病小鼠中,6TG在HUVEC中表现出显著的抗血管性活性,并减少了视网膜血管变化.
- 6TG的抗血管效应被MC5R对手PG20N减弱,这表明MC5R在调解这些效应方面发挥了作用.
结论:
- 6 - 硫黄素 (6TG) 显示出与糖尿病视网膜病变 (DR) 相关的显著抗血管原性质.
- 在DR中观察到的6TG的治疗作用似乎是通过与视网膜黑色皮质受体MC1R和MC5R的相互作用来调节的.
相关概念视频
01:26Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K